IQM
9.12.2021 17:02:06 CET | Business Wire | Press release
In a new work published in Nature Electronics, researchers in Finland have developed a circuit that produces the high-quality microwave signals required to control quantum computers while operating at temperatures near absolute zero. This is a key step towards moving the control system closer to the quantum processor, which may make it possible to greatly increase the number of qubits in the processor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005593/en/
One of the factors limiting the size of quantum computers is the mechanism used to control the qubits in quantum processors. This is normally accomplished using a series of microwave pulses, and because quantum processors operate at temperatures near absolute zero, the control pulses are normally brought into the cooled environment via broadband cables from room temperature.
As the number of qubits grows, so does the number of cables needed. This limits the potential size of a quantum processor, because the refrigerators cooling the qubits would have to become larger to accommodate more and more cables while also working harder to cool them down – ultimately a losing proposition.
A research consortium including Aalto University , VTT Technical Research Centre of Finland , and IQM Quantum Computers has now developed a key component of the solution to this conundrum. ‘We have built a precise microwave source that works at the same extremely low temperature as the quantum processors, approximately -273 degrees,’ says the team leader Mikko Möttönen , Professor at Aalto University and VTT Technical Research Centre of Finland and a Co-Founder and Chief Scientist of IQM.
The new microwave source is an on-chip device that can be integrated with a quantum processor. Less than a millimetre in size, it potentially removes the need for high-frequency control cables connecting different temperatures. With this low-power, low-temperature microwave source, it may be possible to use smaller cryostats while still increasing the number of qubits in a processor.
‘Our device produces one hundred times more power than previous versions, which is enough to control qubits and carry out quantum logic operations,’ says Möttönen. ‘It produces a very precise sine wave, oscillating over a billion times per second. As a result, errors in qubits from the microwave source are very infrequent, which is important when implementing precise quantum logic operations.’
However, a continuous-wave microwave source, such as the one produced by this device, cannot be used as is to control qubits. First, the microwaves must be shaped into pulses. The team is currently developing methods to quickly switch the microwave source on and off.
Even without a switching solution to create pulses, an efficient, low-noise, low-temperature microwave source could be useful in a range of quantum technologies, such as quantum sensors.
‘In addition to quantum computers and sensors, the microwave source can act as a clock for other electronic devices. It can keep different devices in the same rhythm, allowing them to induce operations for several different qubits at the desired instant of time,’ explains Möttönen.
The theoretical analysis and the initial design were carried out by Juha Hassel and others at VTT. Hassel, who started this work at VTT, is currently the head of engineering and development at IQM Quantum Computers, Pan-European leader in quantum computers. The device was then built at VTT and operated by postdoctoral research Chengyu Yan and his colleagues at Aalto University using the OtaNano research infrastructure. Yan is currently an associate professor at Huazhong University of Science and Technology, China. The teams involved in this research are part of the Academy of Finland Centre of Excellence in Quantum Technology (QTF) and the Finnish Quantum Institute (InstituteQ).
Original research paper
Chengyu Yan, Juha Hassel, Visa Vesterinen, Jinli Zhang, Joni Ikonen, Leif Grönberg, Jan Goetz and Mikko Möttönen, A low-noise on-chip coherent microwave source , Nature Electronics, DOI:10.1038/s41928-021-00680-z (2021)
https://doi.org/10.1038/s41928-021-00680-z (link opens after embargo ceases)
Preprint available at any time: https://arxiv.org/pdf/2103.07617
More pictures in the material bank : https://materialbank.aalto.fi/l/sjcg87sHxFfR
About IQM Quantum Computers
IQM is a Pan-European leader in quantum computers.
IQM provides on-site quantum computing for research labs and supercomputing data centers and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has offices in Bilbao, Munich and Espoo and employs over 130 people. More information: www.meetiqm.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005593/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
